Hochtaunus-Kliniken gGmbH

The medical center is at the forefront of research in cervical cancer, focusing on advanced therapeutic combinations to improve patient outcomes. The ongoing studies aim to enhance progression-free survival and overall survival in patients with metastatic, persistent, or recurrent carcinoma of the cervix.

• Combination Chemotherapy
• Immunotherapy Integration
• Targeted Therapy with Bevacizumab

By integrating atezolizumab with standard chemotherapy regimens, the center is pioneering new treatment paradigms that could redefine the management of advanced cervical cancer.

Specializing in endometrial cancer, the center is conducting pivotal trials to assess the efficacy of novel agents like dostarlimab in delaying cancer recurrence. The research targets both recurrent and primary advanced endometrial cancer, with a focus on improving progression-free survival and overall survival.

• Immunotherapy with Dostarlimab
• Combination Therapy Strategies
• Biomarker-Driven Approaches

The center's work in this area is crucial for developing personalized treatment plans that cater to the unique genetic profiles of endometrial cancer patients.

In the realm of ovarian cancer, the center is exploring innovative maintenance therapies post-chemotherapy. The focus is on enhancing the efficacy of durvalumab and olaparib in patients with newly diagnosed advanced ovarian cancer.

• Maintenance Therapy Innovations
• Combination of Immunotherapy and PARP Inhibitors
• First-Line Treatment Efficacy

These studies are pivotal in establishing new standards of care that could significantly improve the quality of life and survival rates for ovarian cancer patients.

The center is advancing the field of advanced therapeutics in oncology, particularly focusing on sacituzumab govitecan for endometrial cancer post-chemotherapy and immunotherapy. The research aims to compare its effectiveness against standard treatments chosen by physicians.

• Novel Antibody-Drug Conjugates
• Comparative Effectiveness Research
• Post-Immunotherapy Strategies

By evaluating the impact of sacituzumab govitecan, the center is contributing to the development of more effective treatment options for patients with limited therapeutic choices.